Biotechnology

Landmark study in JAMA Neurology shows BRIUMVI offers near-zero relapse rates and stable disability, reshaping long-term multiple sclerosis treatment.

A new partnership aims to manufacture a life-saving gene therapy for NKH, a devastating rare disorder, driven by a family's relentless advocacy.

With its burn treatment gaining traction and a pivotal wound care drug in late-stage trials, MediWound prepares to make its case to Wall Street.

With a new regulatory chief, Ray Therapeutics accelerates its mission to bring its goggle-free optogenetic therapies for blindness through clinical trials.

Profitable and with little debt, this holding company is leveraging a diverse portfolio as it prepares for a major stock market uplist. Here's a closer look.

An Indiana firm's implantable pump gains key FDA status, promising a future with less mental burden for Type 1 Diabetes patients. But the road is long.

NRx Pharmaceuticals gets a green light from the FDA to seek broader approval for its ketamine drug, NRX-100, using a novel real-world evidence approach.

Amidst a volatile stock history, GT Biopharma aims to secure vital funding for its innovative NK cell therapy pipeline at a key Toronto conference.

Fortrea splits key roles, dedicating its CMO to scientific strategy and hiring a new president for clinical pharmacology in a bold post-spin-off move.

With a key depression drug nearing Phase 3 and more data imminent, AtaiBeckley is set to make its case to Wall Street at three major March conferences.

As Pasithea Therapeutics heads to a key investor conference, all eyes are on its lead drug, PAS-004, and its potential to treat rare and complex diseases.

A new therapy for a rare brain cancer is one step closer to patients after the FDA accepted tirabrutinib for accelerated review, offering hope where few options exist.

Landmark Phase 3 trial results show psilocybin offers rapid, lasting relief for severe depression, pushing psychedelic medicine closer to the mainstream.

New long-term data shows duvakitug maintained remission in IBD patients for nearly a year, positioning it as a top contender in a new class of therapy.

A new partnership combines AI design with rapid lab testing to crack the code of complex proteins, speeding up drug discovery and opening new frontiers.

Oculis appoints former Cooley partner Katie Kazem as CLO, a strategic move to fortify governance ahead of pivotal data readouts for its late-stage eye drugs.

With a bolstered cash runway from recent funding, Inventiva is all-in on its MASH drug, lanifibranor, racing against giants in a multi-billion dollar market.

London-based Resurrect Bio lands $8.1M led by Corteva to scale its AI-driven gene-editing platform, aiming to resurrect natural plant immunity.

A new study uses PET-CT scans to track CIT-013, a first-in-class antibody targeting the root cause of inflammation in rheumatoid arthritis and HS.

A Swedish biotech and Belgian university secure major EU funding to advance a first-in-class drug against glioblastoma, a notoriously deadly brain tumor.